[Research Progress of C-Myc in Chronic Myelogenous Leukemia --Review].
As a potential target for cancer treatment, the C-Myc high expresses abnormally in a variety of solid tumors and hematological malignancies in humans. In hematologic malignancies, the increasing expression of C-Myc is associated with poor prognosis of patients diffuse large B-cell lymphoma. However, some studies have shown that high expression of C-Myc might be one of the mechanisms of disease progression and abrupt change, therefore, it can promote the transformation of chronic myeloid leukemia. Besides, the high expression of C-Myc may lead to the decrease of the sensitivity of chronic myelogenous leukemia cells to imatinib. Therefore, C-Myc has been concerned in the study of imatinib drug resistance. This review will focuses on the latest research progress on the mechanism of C-Myc in chronic myeloid leukemia in recent years.